Journal scan
| The first 150 words of the full text of this article appear below. |
 |
JOURNALSCAN |
|---|
Please
visit the Heart website (www.heartjnl.com) for links to these
articles
many to full text.
IQBAL MALIK
Editor, JournalScan
| |
ISCHAEMIC HEART DISEASE |
|---|
Another cost effective treatment? n-3 Polyunsaturated fatty acids (n-3 PUFA) have a cost per life-year gained of about £15 000 based on the benefits shown in the GISSI Prevenzione trial. The authors conclude that this is comparable to simvastatin treatment and advocate the addition of n-3 PUFA therapy to treatments currently in use for secondary prevention after myocardial infarction.
1 Franzosi MG, Brunetti M, Marchioli R, Marfisi RM, Tognoni G, Valagussa F. Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione trial. Pharmacoeconomics 2001;19:411-20[Medline].
PTCA or CABG? The ARTS
trial: About 60% of patients treated by coronary angioplasty
(PTCA) or bypass graft surgery (CABG) have multivessel disease which
could feasibly be treated with either procedure.
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
